Hudson Bay Capital Management
VRTX icon

Hudson Bay Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hudson Bay Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.1M Sell
45,000
-119,518
-73% -$55.7M 0.07% 185
2025
Q4 		$74.6M Buy
164,518
+119,203
+263% +$51.4M 0.25% 82
2025
Q3 		$17.7M Sell
45,315
-4,931
-10% -$2.06M 0.06% 250
2025
Q2 		$22.4M Buy
50,246
+405
+0.8% +$187K 0.08% 193
2025
Q1 		$24.2M Buy
49,841
+39,826
+398% +$18.6M 0.07% 235
2024
Q4 		$4.03M Sell
10,015
-19,985
-67% -$9.26M 0.01% 538
2024
Q3 		$14M Sell
30,000
-107,500
-78% -$51.6M 0.06% 224
2024
Q2 		$64.4M Buy
+137,500
New +$59.7M 0.3% 62
2024
Q1 		– Sell
-37,000
Closed -$15.1M – 891
2023
Q4 		$15.1M Buy
37,000
+30,000
+429% +$11.1M 0.1% 129
2023
Q3 		$2.43M Buy
+7,000
New +$2.45M 0.02% 443
2023
Q1 		– Sell
-32,000
Closed -$9.24M – 1003
2022
Q4 		$9.24M Buy
+32,000
New +$9.75M 0.09% 192
2022
Q1 		– Sell
-32,500
Closed -$7.14M – 1320
2021
Q4 		$7.14M Sell
32,500
-30,000
-48% -$5.83M 0.07% 227
2021
Q3 		$11.3M Buy
62,500
+7,500
+14% +$1.46M 0.15% 102
2021
Q2 		$11.1M Buy
55,000
+2,200
+4% +$460K 0.13% 111
2021
Q1 		$11.3M Buy
52,800
+22,800
+76% +$5.01M 0.14% 101
2020
Q4 		$7.09M Buy
30,000
+20,000
+200% +$4.59M 0.08% 170
2020
Q3 		$2.72M Buy
+10,000
New +$2.76M 0.04% 314
2019
Q2 		– Sell
-14,000
Closed -$2.58M – 712
2019
Q1 		$2.58M Buy
+14,000
New +$2.59M 0.03% 421
2018
Q3 		– Sell
-30,000
Closed -$5.34M – 908
2018
Q2 		$5.1M Hold
30,000
– – 0.07% 273
2018
Q1 		$4.89M Sell
30,000
-20,000
-40% -$3.27M 0.1% 237
2017
Q4 		$7.49M Hold
50,000
– – 0.16% 107
2017
Q3 		$7.6M Buy
50,000
+10,000
+25% +$1.51M 0.19% 110
2017
Q2 		$5.16M Buy
40,000
+18,343
+85% +$2.21M 0.1% 185
2017
Q1 		$2.37M Buy
+21,657
New +$1.91M 0.03% 422

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hudson Bay Capital Management's VRTX Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 73% in Q1 2026, selling an estimated $55.7M and leaving 45,000 shares worth $20.1M. The position accounts for 0.07% of the portfolio, ranked #185.

Hudson Bay Capital Management first reported a position in VRTX in Q1 2017 and has held it in 24 quarters since. The position peaked at $74.6M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Hudson Bay Capital Management held 45,000 shares of Vertex Pharmaceuticals worth $20.1M as of Q1 2026.
  • Hudson Bay Capital Management sold 119,518 Vertex Pharmaceuticals shares in Q1 2026, an estimated $55.7M.
  • Vertex Pharmaceuticals made up 0.07% of Hudson Bay Capital Management's portfolio in Q1 2026, its #185 holding.
  • Hudson Bay Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 24 quarters since.
  • Hudson Bay Capital Management's Vertex Pharmaceuticals position peaked at $74.6M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.